SU 5402: Benchmark FGFR3 and VEGFR2 Inhibitor for Receptor Tyrosine Kinase Research

Executive Summary: SU 5402 (SKU A3843) is a selective small-molecule inhibitor targeting VEGFR2 (IC50 = 0.02 μM), FGFR1 (IC50 = 0.03 μM), and PDGFRβ (IC50 = 0.51 μM), with minimal effect on EGFR (IC50 > 100 μM) under cell-free conditions (APExBIO). It blocks FGFR3 phosphorylation, suppressing downstream ERK1/2 and STAT3 signaling and inducing cell cycle arrest in G0/G1 in FGFR3-mutant myeloma cell lines (see related article; this article clarifies quantitative inhibition data). SU 5402 is insoluble in water/ethanol, but dissolves in DMSO at ≥14.8 mg/mL and is recommended for short-term solutions at –20°C. In vivo, 300 ng/kg SU 5402 reduces phosphorylated ERK1/2 in BALB/c mouse tumor models, supporting its use in preclinical oncology workflows. These claims are supported by primary literature and product documentation (Oh et al., 2025).

Biological Rationale

Receptor tyrosine kinases (RTKs) such as VEGFR2, FGFR1/3, PDGFRβ, and EGFR play central roles in cell proliferation, survival, and migration (Oh et al., 2025). Aberrant activation of FGFR3 is a driver of multiple myeloma and select solid tumors. Inhibition of downstream ERK1/2 and STAT3 pathways can arrest cell growth and trigger apoptosis. Targeting RTK signaling is a validated strategy in cancer biology and neurobiology research. SU 5402 enables precise pharmacological interrogation of these pathways in both cancer and iPSC-derived neuronal models (see related article; this article provides updated storage and solubility guidance).

Mechanism of Action of SU 5402

SU 5402 inhibits the kinase activity of VEGFR2, FGFR1, and PDGFRβ by competitively binding to their ATP-binding sites. The compound displays highest affinity for VEGFR2 and FGFR1, with IC50 values of 0.02 μM and 0.03 μM, respectively, as determined in cell-free biochemical assays at 25°C, pH 7.4 (APExBIO). In FGFR3-mutated myeloma lines, SU 5402 blocks FGFR3 phosphorylation, suppressing ERK1/2 and STAT3 activation. This leads to cell cycle arrest at G0/G1 and promotes apoptosis via caspase-dependent mechanisms. The compound has negligible inhibition of EGFR (IC50 > 100 μM), making it highly selective within the RTK family. SU 5402's actions are reversible upon compound washout, supporting its use in temporal signaling studies.

Evidence & Benchmarks

• SU 5402 inhibits VEGFR2 phosphorylation with IC50 = 0.02 μM in vitro at 25°C, pH 7.4 (APExBIO).
• In FGFR3-mutant human myeloma cell lines, SU 5402 at 10 μM induces G0/G1 cell cycle arrest and increases apoptosis rates by >30% after 24 h (internal article); this article details in vivo dosing and storage protocols.
• In BALB/c mice, 300 ng/kg SU 5402 reduces phosphorylated ERK1/2 in tumor xenograft tissues within 2 h of administration (APExBIO).
• SU 5402 is insoluble in water and ethanol, but dissolves in DMSO at concentrations ≥14.8 mg/mL, supporting high stock solution preparation for cell culture assays (APExBIO).
• Latency and reactivation studies in human iPSC-derived neuronal models use RTK inhibitors like SU 5402 to dissect neuron-intrinsic signaling (Oh et al., 2025, DOI).

Applications, Limits & Misconceptions

SU 5402 is widely adopted for:

• Dissecting receptor tyrosine kinase signaling (primarily VEGFR2, FGFR1/3, PDGFRβ) in cancer and developmental biology.
• Modeling targeted inhibition in cell viability, apoptosis, and cell cycle arrest assays.
• Translational studies focusing on FGFR3-driven multiple myeloma and related neoplasms.
• Preclinical in vivo studies at sub-microgram/kg dosing, especially for tumor ERK1/2 pathway modulation.

This article updates earlier reviews (e.g., SU 5402 (SKU A3843): Optimizing RTK Inhibition…) by providing live links to primary stability and dosing data.

Common Pitfalls or Misconceptions

• SU 5402 does not efficiently inhibit EGFR (IC50 > 100 μM under standard conditions); it is not suitable as a pan-RTK inhibitor (APExBIO).
• It is insoluble in water and ethanol; DMSO is required for stock solution preparation. Attempting aqueous dissolution leads to precipitation (APExBIO).
• SU 5402 is designed for in vitro and preclinical research only; no clinical/therapeutic approval exists (APExBIO).
• Long-term storage of DMSO solutions is not recommended due to compound degradation; use freshly prepared solutions and store dry powder at –20°C.
• Off-target effects may occur at concentrations >10 μM; always titrate for minimal effective dose.

Workflow Integration & Parameters

SU 5402 (SKU A3843) from APExBIO is provided as a solid with a molecular weight of 296.33 g/mol. For cell-based assays, dissolve in DMSO to prepare a 10 mM stock; typical final concentrations range from 0.1 to 10 μM. For in vivo xenograft models, dosing of 300 ng/kg (i.p. or i.v.) reduces ERK1/2 phosphorylation within 2 h in BALB/c mice. Store dry powder at –20°C; minimize freeze-thaw cycles. For apoptosis and cell cycle arrest studies, treat cells for 12–48 h and include vehicle controls. SU 5402 is compatible with high-content screening and is validated in both cancer and iPSC-derived neuronal workflows. For protocol optimization and troubleshooting, see this guide; this article adds updated solubility and storage recommendations.

Conclusion & Outlook

SU 5402 remains a gold-standard tool for dissecting receptor tyrosine kinase signaling in cancer and neurobiology research. Its high selectivity for VEGFR2 and FGFR1/3, robust solubility in DMSO, and reproducible in vivo efficacy make it indispensable for apoptosis, cell cycle, and pathway inhibition assays. For authoritative product specifications and batch-specific documentation, visit the APExBIO SU 5402 product page. Ongoing studies are extending its use in neuronal models, including those for viral latency and reactivation (Oh et al., 2025), underscoring its translational relevance.